IN THE SPOTLIGHT

Evaluation of six clinical prognostic scores in NSCLC patients undergoing first line chemoimmunotherapy

Evaluation of six clinical prognostic scores in NSCLC patients undergoing first line chemoimmunotherapy

Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study

Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study

Stage IIIB ROS1-Positive NSCLC management: crizotinib + surgery + TCM achieves exceptionally prolonged PFS (a case report)

Stage IIIB ROS1-Positive NSCLC management: crizotinib + surgery + TCM achieves exceptionally prolonged PFS (a case report)

Osimertinib ± Savolitinib in MET-EGFR NSCLC Trial

Osimertinib ± Savolitinib in MET-EGFR NSCLC Trial

Addressing Access Barriers for HER2-Targeted Therapies in NSCLC

Addressing Access Barriers for HER2-Targeted Therapies in NSCLC

Addressing Access Barriers for HER2-Targeted Therapies in NSCLC

Addressing Access Barriers for HER2-Targeted Therapies in NSCLC